Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 13, Number 2—February 2007
Synopsis

Immune Cell Apoptosis Prevention as Potential Therapy for Severe Infections

Janie Parrino*, Richard S. Hotchkiss†, and Mike Bray*Comments to Author 
Author affiliations: *National Institutes of Health, Bethesda, Maryland, USA; †Washington University School of Medicine, Saint Louis, Missouri, USA;

Main Article

Table 2

Antiapoptotic therapeutic approaches for prevention of lymphocyte apoptosis in murine models of sepsis

StrategyInterventionReference
Prevent triggering of extrinsic pathway
Blockade of Fas ligand by using Fas fusion protein
(27)
Prevent triggering of extrinsic pathway
Prevent Fas expression by using siRNA
(28)
Prevent initiation
Anti-CD40 agonist antibodies
(29)
Prevent initiation
Treatment with Bcl-2 agonist peptides
(30)
Prevent triggering of intrinsic pathway
Antiretroviral protease inhibitors
(31)
Prevent execution phase
Anticaspase-8 siRNA
(28)
Prevent execution phaseTreatment with caspase inhibitors (32,33)

Main Article

References
  1. Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg REJr, Hui JJ, Chang KC, Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans.J Immunol. 2001;166:695263.PubMedGoogle Scholar
  2. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis.N Engl J Med. 2003;348:13850. DOIPubMedGoogle Scholar
  3. Wesche DE, Lomas-Neira JL, Perl M, Chung CS, Ayala A. Leukocyte apoptosis and its significance in sepsis and shock.J Leukoc Biol. 2005;78:32537. DOIPubMedGoogle Scholar
  4. Hotchkiss RS, Osmon SB, Chang KC, Wagner TH, Coopersmith CM, Karl IE. Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways.J Immunol. 2005;174:51108.PubMedGoogle Scholar
  5. Felmet KA, Hall MW, Clark RS, Jaffe R, Carcillo JA. Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure.J Immunol. 2005;174:376572.PubMedGoogle Scholar
  6. Toti P, de Felice C, Occhini R, Schuerfeld K, Stumpo M, Epistolato MC, Spleen depletion in neonatal sepsis and chorioamnionitis.Am J Clin Pathol. 2004;122:76571. DOIPubMedGoogle Scholar
  7. Le Tulzo Y, Pangault C, Gacouin A, Guilloux V, Tribut O, Amiot L, Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome.Shock. 2002;18:48794. DOIPubMedGoogle Scholar
  8. Hotchkiss RS, Swanson PE, Cobb JP, Jacobson A, Buchman TG, Karl IE. Apoptosis in lymphoid and parenchymal cells during sepsis: findings in normal and T- and B-cell-deficient mice.Crit Care Med. 1997;25:1298307. DOIPubMedGoogle Scholar
  9. Efron PA, Tinsley K, Minnich DJ, Monterroso V, Wagner J, Lainee P, Increased lymphoid tissue apoptosis in baboons with bacteremic shock.Shock. 2004;21:56671. DOIPubMedGoogle Scholar
  10. Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers.Lancet Infect Dis. 2004;4:48798. DOIPubMedGoogle Scholar
  11. Baize S, Leroy EM, Georges-Courbot MC, Capron M, Lansoud-Soukate J, Debre P, Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients.Nat Med. 1999;5:4236. DOIPubMedGoogle Scholar
  12. Sanchez A, Lukwiya M, Bausch D, Mahanty S, Sanchez AJ, Wagoner KD, Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels.J Virol. 2004;78:103707. DOIPubMedGoogle Scholar
  13. Reed DS, Hensley LE, Geisbert JB, Jahrling PB, Geisbert TW. Depletion of peripheral blood T lymphocytes and NK cells during the course of Ebola hemorrhagic fever in cynomolgus macaques.Viral Immunol. 2004;17:390400. DOIPubMedGoogle Scholar
  14. Gibb TR, Bray M, Geisbert TW, Steele KE, Kell WM, Davis KJ, Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice.J Comp Pathol. 2001;125:23342. DOIPubMedGoogle Scholar
  15. Geisbert TW, Hensley LE, Gibb TR, Steele KE, Jaax NK, Jahrling PB. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses.Lab Invest. 2000;80:17186. DOIPubMedGoogle Scholar
  16. Inglesby TV, O’Toole T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Anthrax as a biological weapon, 2002: updated recommendations for management.JAMA. 2002;287:223652. DOIPubMedGoogle Scholar
  17. Grinberg LM, Abramova FA, Yampolskaya OV, Walker DH, Smith JH. Quantitative pathology of inhalational anthrax I: quantitative microscopic findings.Mod Pathol. 2001;14:48295. DOIPubMedGoogle Scholar
  18. Alileche A, Serfass ER, Muehlbauer SM, Porcelli SA, Brojatsch J. Anthrax lethal toxin-mediated killing of human and murine dendritic cells impairs the adaptive immune response.PLoS Pathog. 2005;1:e19. DOIPubMedGoogle Scholar
  19. Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.JAMA. 2000;283:228190. DOIPubMedGoogle Scholar
  20. Viboud GI, Bliska JB. Yersinia outer proteins: role in modulation of host cell signaling responses and pathogenesis.Annu Rev Microbiol. 2005;59:6989. DOIPubMedGoogle Scholar
  21. Lathem WW, Crosby SD, Miller VL, Goldman WE. Progression of primary pneumonic plague: a mouse model of infection, pathology, and bacterial transcriptional activity.Proc Natl Acad Sci U S A. 2005;102:1778691. DOIPubMedGoogle Scholar
  22. Alonso A, Bottini N, Bruckner S, Rahmouni S, Williams S, Schoenberger SP, Lck dephosphorylation at Tyr-394 and inhibition of T cell antigen receptor signaling by Yersinia phosphatase YopH.J Biol Chem. 2004;279:49228. DOIPubMedGoogle Scholar
  23. Sebbane F, Gardner D, Long D, Gowen BB, Hinnebusch BJ. Kinetics of disease progression and host response in a rat model of bubonic plague.Am J Pathol. 2005;166:142739.PubMedGoogle Scholar
  24. Hotchkiss RS, Swanson PE, Knudson CM, Chang KC, Cobb JP, Osborne DF, Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis.J Immunol. 1999;162:414856.PubMedGoogle Scholar
  25. Iwata A, Stevenson VM, Minard A, Tasch M, Tupper J, Lagasse E, Over-expression of Bcl-2 provides protection in septic mice by a trans effect.J Immunol. 2003;171:313641.PubMedGoogle Scholar
  26. Bommhardt U, Chang KC, Swanson PE, Wagner TH, Tinsley KW, Karl IE, Akt decreases lymphocyte apoptosis and improves survival in sepsis.J Immunol. 2004;172:758391.PubMedGoogle Scholar
  27. Chung CS, Yang S, Song GY, Lomas J, Wang P, Simms HH, Inhibition of Fas signaling prevents hepatic injury and improves organ blood flow during sepsis.Surgery. 2001;130:33945. DOIPubMedGoogle Scholar
  28. Wesche-Soldato DE, Chung CS, Lomas-Neira J, Doughty LA, Gregory SH, Ayala A. In vivo delivery of caspase-8 or Fas siRNA improves the survival of septic mice.Blood. 2005;106:2295301. DOIPubMedGoogle Scholar
  29. Schwulst SJ, Grayson MH, Dipasco PJ, Davis CG, Brahmbhatt TS, Ferguson TA, Agonistic monoclonal antibody against CD40 receptor decreases lymphocyte apoptosis and improves survival in sepsis.J Immunol. 2006;177:55765.PubMedGoogle Scholar
  30. Hotchkiss RS, McConnell KW, Bullok K, Davis CG, Chang KC, Schwulst SJ, TAT-BH4 and TAT-Bcl-xL peptides protect against sepsis-induced lymphocyte apoptosis in vivo.J Immunol. 2006;176:54717.PubMedGoogle Scholar
  31. Weaver JG, Tarze A, Moffat TC, Lebras M, Deniaud A, Brenner C, Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor.J Clin Invest. 2005;115:182838. DOIPubMedGoogle Scholar
  32. Hotchkiss RS, Tinsley KW, Swanson PE, Chang KC, Cobb JP, Buchman TG, Prevention of lymphocyte cell death in sepsis improves survival in mice.Proc Natl Acad Sci U S A. 1999;96:145416. DOIPubMedGoogle Scholar
  33. Hotchkiss RS, Chang KC, Swanson PE, Tinsley KW, Hui JJ, Klender P, Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte.Nat Immunol. 2000;1:496501. DOIPubMedGoogle Scholar
  34. Chung CS, Xu YX, Wang W, Chaudry IH, Ayala A. Is Fas ligand or endotoxin responsible for mucosal lymphocyte apoptosis in sepsis?Arch Surg. 1998;133:121320. DOIPubMedGoogle Scholar
  35. Hoogenboom HR. Selecting and screening recombinant antibody libraries.Nat Biotechnol. 2005;23:110516. DOIPubMedGoogle Scholar
  36. Methot N, Huang J, Coulombe N, Vaillancourt JP, Rasper D, Tam J, Differential efficacy of caspase inhibitors on apoptosis markers during sepsis in rats and implication for fractional inhibition requirements for therapeutics.J Exp Med. 2004;199:199207. DOIPubMedGoogle Scholar
  37. Martinon F, Tschopp J. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases.Cell. 2004;117:56174. DOIPubMedGoogle Scholar
  38. Perfettini JL, Kroemer G. Caspase activation is not death.Nat Immunol. 2003;4:30810. DOIPubMedGoogle Scholar
  39. Chun HJ, Zheng L, Ahmad M, Wang J, Speirs CK, Siegel RM, Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency.Nature. 2002;419:3959. DOIPubMedGoogle Scholar
  40. Cauwels A, Janssen B, Waeytens A, Cuvelier C, Brouckaert P. Caspase inhibition causes hyperacute tumor necrosis factor-induced shock via oxidative stress and phospholipase A2.Nat Immunol. 2003;4:38793. DOIPubMedGoogle Scholar

Main Article

Page created: June 29, 2010
Page updated: June 29, 2010
Page reviewed: June 29, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external